Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study - Archive ouverte HAL Access content directly
Journal Articles Blood Advances Year : 2020

Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study

(1) , (2) , (1) , (3) , (4) , (5) , (6) , (7) , (2) , (8) , (9) , (10) , (11) , (12, 13) , (14) , (15) , (16, 17) , (18) , (19) , (2) , (20)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
Rene-Olivier Casasnovas
François Lemonnier
Roch Houot
Thierry Fest

Abstract

Abstract Complete molecular response (CMR) after first-line immunochemotherapy reflects treatment efficacy and may predict prognosis in patients with follicular lymphoma (FL). RELEVANCE is the first phase 3 trial comparing the chemotherapy-free regimen lenalidomide/rituximab (R2) vs rituximab/chemotherapy (R-Chemo) in previously untreated FL patients (ClinicalTrials.gov identifier: NCT01650701). The objective of the minimal residual disease (MRD) analysis was to determine the ability of a chemotherapy-free regimen to induce CMR. Of 440 French patients participating in the Lymphoma Study Association (LYSA) RELEVANCE MRD study, all 222 patients with a BIOMED-2–detectable BCL2-JH translocation at diagnosis were analyzed. MRD was quantified by droplet digital polymerase chain reaction with a sensitivity ≤10−4. At week 24 (end of induction treatment), 98% and 78% of patients achieved CMR in peripheral blood (PB) and bone marrow (BM), respectively. Achievement of CMR (in PB and/or BM) had a significant impact on progression-free survival (PFS), with 3-year PFS of 84% and 55% for patients with CMR and detectable MRD, respectively (P = .015). CMR at week 24 was reached more frequently in the R2 arm (105/117; 90%) than in the R-Chemo arm (70/90; 77%) (P = .022). The poor prognostic value in terms of PFS for the persistence of molecular disease was observed irrespective of treatment arm (interaction test, P = .31). In agreement with the clinical results of the RELEVANCE trial, our results show that R2 immunomodulatory treatment in first-line FL can achieve high rates of CMR.
Embargoed file
Embargoed file
Ne sera jamais visible

Dates and versions

inserm-03498367 , version 1 (21-12-2021)

Identifiers

Cite

Marie-Helene Delfau-Larue, Marie-Laure Boulland, Asma Beldi-Ferchiou, Pierre Feugier, Hervé Maisonneuve, et al.. Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study. Blood Advances, 2020, 4 (14), pp.3217-3223. ⟨10.1182/bloodadvances.2020001955⟩. ⟨inserm-03498367⟩
55 View
1 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More